A Senate bill seeking crucial modifications to the operation of patent challenges at the Patent Trial and Appeal Board (PTAB), has come under fire from a consortium of ten think tanks and consumer groups. Their main concern? They believe the bill will perpetuate the status quo of Americans paying higher prices for prescription drugs than counterparts in other parts of the world.
Taking a stand against the proposed bill, these groups argue that rather than reducing drug prices, as it intends to, it might inadvertently serve to uphold the current disparities. The comprehensive specifics of the proposed changes, however, as well as the groups’ planned actions to oppose the bill, remain undisclosed to the public due to the restricted access to the full text of the article.
While there might be a divergence of views, it is clear that the proposed PTAB reform is controversial, implicating both the future of legal patent proceedings and the cost of prescription drugs in the United States.
For more detailed context and information on the issue, the full article can be accessed with a subscription on Law360.